{
      "eprintid": 65786,
      "creators": [
        {
          "name": {
            "honourific": null,
            "given": "Alimbayeva",
            "family": "Sevara",
            "lineage": null
          }
        },
        {
          "name": {
            "family": "Dilmurod",
            "lineage": null,
            "given": "Axadullayev",
            "honourific": null
          }
        },
        {
          "name": {
            "given": "Madaminov",
            "honourific": null,
            "family": "Akhmadjan",
            "lineage": null
          }
        }
      ],
      "abstract": "Breast cancer (BC) remains a leading cause of female morbidity and mortality globally. Modern management has shifted from a \"one-size-fits-all\" approach to molecular-subtype-driven personalized therapy. This study evaluates the clinical efficacy of dose-dense neoadjuvant chemotherapy (NACT) combined with targeted hormonal maintenance in patients with Luminal B HER2-negative breast cancer (stages IIA-IIIB). Analyzing a cohort of 84 patients, we assessed the objective response rate (ORR) and the frequency of pathological complete response (pCR). Statistical analysis using Student's t-test and $\\chi^2$ criteria demonstrated that the integration of taxane-based dose-dense regimens significantly improves surgical outcomes compared to standard FEC protocols ($p < 0.05$). The findings emphasize the necessity of tailoring systemic therapy based on Ki-67 proliferation indices and lymphovascular invasion markers to optimize long-term survival.",
      "title": "INTEGRATED THERAPEUTIC STRATEGIES AND PERSONALIZED APPROACHES IN THE MANAGEMENT OF LUMINAL B HER2-NEGATIVE BREAST CANCER: A CLINICAL-STATISTICAL ANALYSIS",
      "status_changed": "2026-05-26 15:55:55",
      "eprint_status": "archive",
      "lastmod": "2026-05-26 15:55:55",
      "publication": "Multidisciplinary Journal of Science and Technology",
      "sword_depositor": 1,
      "dir": "disk0/00/06/57/86",
      "keywords": "Breast cancer, Luminal B, Neoadjuvant chemotherapy, Ki-67, Clinical Oncology, Biostatistics, Personalized Medicine.",
      "publisher": "Center for Tech and Media Research",
      "rev_number": 1,
      "datestamp": "2026-05-26 15:55:55",
      "note": "Imported from MJST Journal (OAI id oai:ojs.pkp.sfu.ca:article/6884)",
      "metadata_visibility": "show",
      "date_type": "published",
      "ispublished": "pub",
      "official_url": "https://mjstjournal.com/index.php/mjst/article/view/6884",
      "subjects": [
        "Breast cancer, Luminal B, Neoadjuvant chemotherapy, Ki-67, Clinical Oncology, Biostatistics, Personalized Medicine."
      ],
      "userid": 1,
      "id_number": "oai:ojs.pkp.sfu.ca:article/6884",
      "full_text_status": "none",
      "type": "article",
      "date": "2026-02-22",
      "uri": "https://arxiv.universalpublishings.com/id/eprint/65786"
    }